Embecta Faces Securities Class Action Over Insulin Needle Business

The legal action, currently under investigation by the firm Hagens Berman, targets claims made by Embecta management between November 25, 2025, and May 4, 2026. During this period, the company repeatedly described its pen needle portfolio as resilient and stable. Plaintiffs contend these assurances were false, arguing that leadership ignored significant competitive market share losses and declining retail volume.

The discrepancy came to light on May 5, 2026, when the company reported second-quarter fiscal results that shattered previous guidance. Embecta slashed its full-year adjusted EPS forecast by approximately 43% and cut its quarterly dividend from $0.15 to $0.01 per share—a 93% reduction. Reed Kathrein, a partner at Hagens Berman, noted that the firm is scrutinizing whether these prior positive statements were intentionally misleading given the subsequent collapse in financial performance.

Investors who held common stock during the class period have until August 17, 2026, to file as a lead plaintiff. Hagens Berman is also inviting whistleblowers with non-public information regarding the company's internal practices to come forward, citing the potential for SEC-backed rewards in cases involving corporate negligence.